Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

Subtypes and the Shimoyama Classification

At a Glance

Adult T-cell leukemia/lymphoma (ATLL) is categorized into four subtypes—Acute, Lymphoma, Chronic, and Smoldering—using the Shimoyama classification. This subtyping relies on specific lab tests to determine if a patient needs immediate, intensive treatment or watchful waiting.

The most important question your medical team will answer after your diagnosis is: “Which subtype do I have?” Unlike many other cancers that are staged by number (Stage I to IV), Adult T-cell leukemia/lymphoma (ATLL) is classified into four distinct subtypes using a system called the Shimoyama Classification [1][2].

Knowing your subtype is critical because it acts as the master key for your treatment plan [3]. It tells your doctors whether your disease requires immediate, intensive therapy or if it can be safely monitored over time.

The Two Categories: Aggressive vs. Indolent

Doctors group the four subtypes into two broader categories based on how the disease behaves:

  • Aggressive ATLL: These subtypes grow quickly and usually require immediate treatment with chemotherapy or stem cell transplant [4][5]. This category includes the Acute, Lymphoma, and Unfavorable Chronic subtypes [6].
  • Indolent ATLL: These subtypes grow more slowly. In many cases, they are managed with “watchful waiting” (active surveillance) or milder therapies until the disease shows signs of changing [7][8]. This category includes Smoldering and Favorable Chronic subtypes [9].

The Shimoyama Classification Matrix

Your subtype is determined by a combination of your symptoms and specific laboratory values.

Subtype Key Characteristics Typical Lab Findings
Acute Most common aggressive form; involves blood, lymph nodes, and organs [1]. High LDH (Lactate Dehydrogenase), high Calcium, and high white blood cell count [10].
Lymphoma Primarily affects the lymph nodes; few or no cancer cells in the blood [1]. High LDH and high Calcium; normal white blood cell count [1].
Chronic Can be “Favorable” or “Unfavorable”; may have mild blood involvement [6]. Elevated LDH, BUN (Blood Urea Nitrogen), or low Albumin marks the “Unfavorable” type [9].
Smoldering Often involves only the skin or lungs; very slow-growing [11]. Normal LDH and normal Calcium; low number of cancer cells in blood [1].

Defining the Laboratory “Red Flags”

Your doctor uses several blood markers to draw the line between these subtypes:

  • Lactate Dehydrogenase (LDH): A high level suggests that cells are turning over very rapidly, which is a sign of aggressive disease [12].
  • Calcium: Aggressive ATLL often causes hypercalcemia (dangerously high blood calcium), which occurs when cancer cells cause bone breakdown [1][13].
  • BUN (Blood Urea Nitrogen) and Albumin: These are used specifically to split the Chronic subtype. If BUN is high or Albumin is low, the disease is considered “Unfavorable” and is treated more aggressively [9][14].
  • sIL-2R (Soluble Interleukin-2 Receptor): While not part of the original criteria, this is now a vital marker. Very high levels (>5,000 U/mL) often signal a higher risk of the disease becoming more aggressive [10][14].

Why Subtyping Matters for You

If you have an Indolent subtype (Smoldering or Favorable Chronic), starting intensive chemotherapy too early may not improve your long-term outcome and could cause unnecessary side effects [8]. Conversely, if you have an Aggressive subtype, your team will likely move very quickly to start powerful treatments to get the disease under control [5].

Be aware that ATLL can “transform,” meaning an indolent subtype can become aggressive over time [15]. This is why frequent blood tests and monitoring are a standard part of life for those in the “watchful waiting” phase [7].

Common questions in this guide

What are the four subtypes of ATLL?
The four subtypes of Adult T-cell leukemia/lymphoma are Acute, Lymphoma, Chronic, and Smoldering. Your doctors determine your subtype using the Shimoyama classification system, which evaluates your specific symptoms and blood test results.
What is the difference between aggressive and indolent ATLL?
Aggressive ATLL grows quickly and usually requires immediate treatment, such as chemotherapy or a stem cell transplant. Indolent ATLL grows much more slowly and is often managed with active surveillance, also known as watchful waiting.
Why is the Shimoyama classification important for my diagnosis?
The Shimoyama classification acts as the master key for your treatment plan. It tells your doctor exactly which subtype you have, ensuring you receive the right level of care while avoiding unnecessary early treatments for slower-growing disease.
What does an unfavorable chronic ATLL diagnosis mean?
Chronic ATLL is considered unfavorable if specific blood markers, such as elevated Blood Urea Nitrogen (BUN) or low albumin, are present. This unfavorable status indicates that the disease may act more aggressively and typically requires quicker, more intensive treatment.
Can an indolent ATLL subtype change into an aggressive one?
Yes, indolent subtypes like smoldering or favorable chronic ATLL can transform into aggressive forms over time. This is why regular blood tests and close monitoring by your doctor are essential, even if you are only in the watchful waiting phase.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the Shimoyama criteria, what is my specific subtype?
  2. 2.Am I classified as 'Favorable' or 'Unfavorable' Chronic, and what does that mean for how quickly we start treatment?
  3. 3.What were my specific values for LDH, BUN, Albumin, and Calcium at diagnosis?
  4. 4.Do I have any 'extranodal' involvement, such as in my skin, lungs, or liver?
  5. 5.How often will we repeat these lab tests to monitor if my subtype is changing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    HTLV-1-Associated Lymphoma Presented as Massive Lymphadenopathy.

    Chen PT, Onukogu D, Gotlieb G, et al.

    Journal of investigative medicine high impact case reports 2021; (9()):23247096211013235 doi:10.1177/23247096211013235.

    PMID: 33969717
  2. 2

    Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study.

    Imaizumi Y, Iwanaga M, Nosaka K, et al.

    Cancer science 2020; (111(12)):4567-4580 doi:10.1111/cas.14658.

    PMID: 32976684
  3. 3

    An update on the developments in the treatment of adult T-cell leukemia-lymphoma: current knowledge and future perspective.

    Makiyama J, Ishitsuka K, Munakata W, et al.

    Japanese journal of clinical oncology 2023; (53(12)):1104-1111 doi:10.1093/jjco/hyad108.

    PMID: 37592900
  4. 4

    Adult T-cell Leukemia/Lymphoma: A Problem Abroad and at Home.

    Dittus C, Sloan JM

    Hematology/oncology clinics of North America 2017; (31(2)):255-272 doi:10.1016/j.hoc.2016.11.005.

    PMID: 28340877
  5. 5

    Clinical characteristics, genetic alterations, and prognosis of adult T-cell leukemia/lymphoma: an 11-year multicenter retrospective study in China.

    Luo L, Chen Y, Wu Z, et al.

    American journal of cancer research 2024; (14(4)):1649-1661 doi:10.62347/RARP1733.

    PMID: 38726267
  6. 6

    Diagnosis and management of adult T-cell leukemia/lymphoma.

    Ishitsuka K

    Seminars in hematology 2021; (58(2)):114-122 doi:10.1053/j.seminhematol.2021.02.005.

    PMID: 33906721
  7. 7

    CD4+ CADM1+ cell percentage predicts disease progression in HTLV-1 carriers and indolent adult T-cell leukemia/lymphoma.

    Makiyama J, Kobayashi S, Watanabe E, et al.

    Cancer science 2019; (110(12)):3746-3753 doi:10.1111/cas.14219.

    PMID: 31642546
  8. 8

    Adult T-cell leukemia/lymphoma treatment in Bahia, Brazil.

    Oliveira PD, Gomes Í, Souza VH, et al.

    Revista brasileira de hematologia e hemoterapia 2017; (39(1)):13-19 doi:10.1016/j.bjhh.2016.09.012.

    PMID: 28270340
  9. 9

    Current and emerging therapeutic strategies in adult T-cell leukemia-lymphoma.

    Katsuya H

    International journal of hematology 2023; (117(4)):512-522 doi:10.1007/s12185-023-03572-4.

    PMID: 36862273
  10. 10

    Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

    Fuji S, Yamaguchi T, Inoue Y, et al.

    Haematologica 2017; (102(7)):1258-1265 doi:10.3324/haematol.2017.164996.

    PMID: 28341734
  11. 11

    Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review.

    Letafati A, Soheili R, Norouzi M, et al.

    Medical oncology (Northwood, London, England) 2023; (40(10)):295 doi:10.1007/s12032-023-02166-8.

    PMID: 37689806
  12. 12

    Adult T-cell Leukemia/Lymphoma as a Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis.

    Takajo I, Umekita K, Ikei Y, et al.

    Internal medicine (Tokyo, Japan) 2018; (57(14)):2071-2075 doi:10.2169/internalmedicine.0308-17.

    PMID: 29491299
  13. 13

    Hypercalcemia as the Initial Presentation of Acute T-cell Leukemia/Lymphoma.

    Ramachandran V

    Cureus 2022; (14(3)):e23705 doi:10.7759/cureus.23705.

    PMID: 35505762
  14. 14

    Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.

    Kameda T, Shide K, Tahira Y, et al.

    Viruses 2022; (14(4)) doi:10.3390/v14040710.

    PMID: 35458440
  15. 15

    Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study.

    Imaizumi Y, Iwanaga M, Nosaka K, et al.

    International journal of hematology 2023; (117(2)):206-215 doi:10.1007/s12185-022-03473-y.

    PMID: 36308678

This page explains ATLL subtypes and the Shimoyama classification for educational purposes only. Always consult your hematologist or oncologist to understand your specific lab results, diagnosis, and treatment plan.

Get notified when new evidence is published on Adult T-cell leukemia/lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.